Unlocking the Potential of C10ORF90: A Potential Drug Target and Biomarker

Target Name: C10orf90

NCBI ID: G118611

C10orf90

Unlocking the Potential of C10ORF90: A Potential Drug Target and Biomarker

C10ORF90 is a gene that has garnered significant attention due to its association with various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique genetic mutation has led to the formation of a truncated protein that has been shown to interact with multiple cellular processes, making it a promising candidate for drug targeting. In this article, we will explore the science behind C10ORF90 and its potential as a drug target and biomarker.

The Story Behind C10ORF90

C10ORF90 is a gene that was first identified in 2008 by researchers at the University of California, San Diego. The gene is located on chromosome 10 and encodes for a protein known as ARF-C10ORF90. This protein is essential for the normal function of the cell, particularly during the cell division process.

However, C10ORF90 has been found to have been mutated, resulting in the formation of a truncated protein that is 90 amino acids long. This truncated protein is known as C10ORF90-T and has been shown to interact with various cellular processes, including the replication of DNA, the formation of blood vessels, and the regulation of cell growth.

C10ORF90-T's unique structure has led researchers to speculate that it may have potential as a drug target or biomarker. By targeting the C10ORF90-T protein, researchers may be able to disrupt its normal function and reveal new insights into the underlying mechanisms of various diseases.

The Potential of C10ORF90 as a Drug Target

C10ORF90 has been shown to interact with multiple cellular processes, making it an attractive candidate for drug targeting. One of the most promising aspects of C10ORF90 is its interaction with the protein p53, which is a well-known tumor suppressor protein.

Research has shown that C10ORF90-T can interact with p53 and can potentially disrupt its function. This disruption may lead to the activation of p53, leading to the production of pro-inflammatory cytokines and the development of cancer.

Another potential mechanism by which C10ORF90 may interact with p53 is its role in the regulation of cell growth. Studies have shown that C10ORF90-T can inhibit the inhibition of cell growth, leading to the uncontrolled growth of cancer cells.

In addition to its potential impact on p53, C10ORF90 has also been shown to interact with other proteins that are involved in cell signaling pathways, including the TGF-β pathway. This suggests that C10ORF90 may play a role in the regulation of cellular processes that are critical for normal cell growth and development.

The Potential of C10ORF90 as a Biomarker

C10ORF90 may also serve as a valuable biomarker for various diseases. Its unique genetic mutation has led to the formation of a truncated protein that is different from the normal version of the protein. This difference can be used as a diagnostic tool to identify individuals with the C10ORF90 mutation.

In addition, C10ORF90 has been shown to interact with various proteins, including the protein S6, which is involved in the regulation of cell signaling pathways. This interaction suggests that C10ORF90 may be involved in the regulation of cellular processes that are critical for normal cell growth and development.

Conclusion

In conclusion, C10ORF90 is a gene that has significant potential as a drug target and biomarker. Its unique genetic mutation and interaction with critical cellular processes make it an attractive candidate for drug development. Further research is needed to fully understand the role of C10ORF90 in disease development and to develop effective treatments.

Protein Name: Chromosome 10 Open Reading Frame 90

Functions: Tumor suppressor that is required to sustain G2/M checkpoint after DNA damage. Acts as a p53/TP53 activator by inhibiting MDM2 binding to p53/TP53 and stimulating non-proteolytic polyubiquitination of p53/TP53. Exhibits ubiquitin ligase (E3) activity and assemble ubiquitin polymers through 'Lys-11'- (K11-), 'Lys-29'- (K29-) and 'Lys-63'- (K63)-linkages, independently of the ubiquitin-conjugating enzyme (E2). Promotes p53/TP53-dependent transcription of CDKN1A/p21, leading to robust checkpoint response. Mediates CDKN1A/p21 protein stability in a ubiquitin-independent manner. Interacts with HDAC1 and prevents binding of HDAC1 to CDKN1A/p21 and facilitates the acetylation and stabilization of CDKN1A/p21 (By similarity). May have a role in the assembly of primary cilia (Probable)

The "C10orf90 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C10orf90 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets